Follicular Thyroid Carcinoma Treatment Market Growth Focusing on Trends & Innovations During the Period Until 2027

List of Pipeline Drugs and Investment by Major Companies in R&D Propelled Follicular Thyroid Carcinoma Treatment Market

Thyroid gland produces thyroid hormone which is required by the body to regulate metabolism. Follicles that comprise the thyroid, are the functional and structural units of the gland. Follicular thyroid carcinoma is a tumor of the follicular cells which are lined by cuboidal epithelial cells and have capsular and vascular invasive properties.

Report overview @ https://www.transparencymarketresearch.com/follicular-thyroid-carcinoma-treatment-market.html

Compared to follicular carcinoma, follicular adenoma is benign and occurs more commonly with a ratio estimated to be 5 to 1. Follicular carcinoma can be of two types, minimally invasive and invasive, based on its morphologic criteria. Minimally invasive follicular carcinoma is an encapsulated tumor with microscopic penetration of the tumor capsule without vascular invasion. Invasive follicular carcinoma is a follicular carcinoma with vascular invasion and extension beyond the tumor capsule into the adjacent thyroid parenchyma.

Major players are focused in developing effective drugs to treat follicular thyroid cancer through their diverse range of product pipelines. REVLIMID (lenalidomide), which is the product of Celgene Corporation, is currently under phase 2 clinical trial for therapy of radioiodine-unresponsive papillary & follicular thyroid carcinomas.

Request a Brochure of Follicular Thyroid Carcinoma Treatment Market Report –
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=74164

Key Drivers and Restraints of Global Follicular Thyroid Carcinoma Treatment Market

Follicular thyroid cancer accounts for 10 to 15% of all thyroid cancers. It occurs more often in women and older patients with a female-to-male ratio of 3:1 and a mean age of 60 years at the time of diagnosis. According to the American Society of Clinical Oncology (ASCO), estimated 52,070 adults (14,260 men and 37,810 women) in the U.S. are diagnosed with thyroid cancer in 2019. Thus, rise in cases of follicular thyroid cancer is propelling the follicular thyroid carcinoma treatment market.

Increase in drug approval is also fueling the follicular thyroid carcinoma treatment market growth. FDA granted several programs, in order to increase the availability of drugs to treat follicular thyroid carcinoma disease. In 2015, FDA approved a targeted therapy called lenvatinib (Lenvima, E7080) for later-stage differentiated thyroid cancer when surgery, I-131 treatment, or both have not worked.

However, product recall of a few drugs is restraining the follicular thyroid carcinoma treatment market. According to the FDA statement, in August 2018, Westminster Pharmaceuticals recalled Levothyroxine and Liothyronine tablets as a precautionary measure.

Surgery to Witness High Demand

Based on treatment type, the global follicular thyroid carcinoma treatment market is segmented into: Surgery, Radioactive Iodine (RAI), Drugs, Chemotherapy, External Radiotherapy, Thyroxin Treatment, and Others. Surgery is further sub-segmented into thyroid lobectomy, thyroidectomy, and others.

Types of treatment for follicular thyroid carcinoma depend on types and stages of the cancer. Most cancers are treated with removal of thyroid gland (thyroidectomy) or by just removing the side of the thyroid containing the tumor (lobectomy). Thus, the surgical segment holds major share of the market.

For More Actionable Insights into The Competitive Landscape of Follicular Thyroid Carcinoma Treatment Market , Pre Book This Report –
https://www.transparencymarketresearch.com/checkout.php?rep_id=74164<ype=S

Oncology Centers Segment to Witness Highest Growth

Based on end-user, the global follicular thyroid carcinoma treatment market can be divided into: Hospitals, Oncology Centers, Research Institutes, and Others

In terms of revenue, hospitals dominated the market in 2018 due to large number of procedures performed in these facilities

The oncology centers segment is anticipated to grow with the highest CAGR during the forecast period. This can be attributed to presence of developed technologies and availability of multiple options for follicular thyroid carcinoma treatment.

Various medical institutions and research centers are continuously investing in their research to develop innovative treatment process.

North America to dominate Global Follicular Thyroid Carcinoma Treatment Market

In terms of region, the global follicular thyroid carcinoma treatment market can be divided into: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa

North America dominated the global follicular thyroid carcinoma treatment market in 2018 and is expected to maintain the position during the forecast period. This growth is due to the increase in demand for minimally invasive treatments and increase in focus on patient safety as well as advancement in technologies and established distribution channels.

However, owing to increase in health care expenditure and improvement in health care facilities, Asia Pacific is projected to register the highest growth rate during the forecast period

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.